FDA grants Bayer’s HYRNUO accelerated approval for HER2-mutated lung cancer
AI Summary- U.S. FDA granted Bayer’s HYRNUO accelerated approval for HER2-mutated lung cancer.
- HYRNUO is identified as a first-line targeted therapy for eligible patients.
- Bayer’s treatment is also known by the generic name sevabertinib.